1. Claim 1: a formula compound (1),or one of its pharmaceutically acceptable salts, where: R¹ is selected from C₃₋₈ cycloalkyl,C₂₋₆ heterocyclyl,arilo Cand heteroaryl C₁₋₉,Each of these substitutes is replaced by one to five substitutes, which are independently selected among halo, oxo, CN and R1,And R2；Each one,R830808,and R⁵ is independently selected from hydrogen, halo, -OH, -CN, C₁₋₃ alkyl,and C₁₋₃ haloalkyl；R³ is selected from hydrogen, C₁₋₃ alkyl,and C₁₋₃ haloalkyl；each of R⁶ and R⁷ is independently selected from hydrogen, C₁₋₃ alkyl,and C₁₋₃ haloalkyl；R831222 was selected from hydrogen, methyl and y-nh832222；R⁹ is selected from hydrogen, halo, -CN, C₁₋₃ haloalkyl,-Or18310,-C (O) R-C (O) OR-C (O) N (R) R-C (O) N (R) OR-C (O) N (R) S (O) R-SR18310,-S (O) R-S (O) Ry -S (O) N (R) RO r831222 from - nh-y-ch8322 -,R831222 and r8313；together with the carbon atoms to which they are attached, they form a C₂₋₄ heteroarylene having 5 ring atoms and between 1 and 3 heteroatoms, each of the heteroatoms is nitrogen, and where the C₂₋₄ heteroarylene is optionally substituted with R¹²；R830404 selected from Halo - Oh, rent c832131；-NHR¹⁶,y -NHC (O) REach R1 R1 is independently selected between - or1 cubes,-N (R) R-NR C (O) R-NHC (O) NR R-NR C (O) NHR-C (O) R-C (O) OR-C (O) N (R) R-C (O) N (R) OR-C (O) N (R) S (O) R-N (R) S (O) R-SRI-S (O) R-S (O) Ry -S (O) N (R) Reach R¹² is independently selected from C₁₋₆ alkyl,C₂₋₆ alkenyl,1. C 83228331 asphalt；cicloalquilo C - (CH) -arilo C - (CH) -3. Isopropene-c833228321-832626 - (ch-83222244)；And heterosexual c83218c83318329 - (ch83222)； 8344； -,a. Each alternative is replaced by one to five alternatives, which are selected separately among halogenation, oxo CN and c832183316c；haloalkyl C₁₋₆ and R¹⁵；(a) Each R3 and r830808 shall be independently selected from (a) hydrogen and (b) c83218c831832626；C₂₋₆ alkenyl,1. C 83228331 asphalt；cicloalquilo C - (CH) -arilo C - (CH) -3. Isopropene-c833228321-832626 - (ch-83222244)；And heterosexual c83
